

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19

SUPPLEMENTARY INFORMATION for

**TLR4 is a regulator of trained immunity in a murine model of
Duchenne muscular dystrophy**


Salyan Bhattarai^{1,2}, Qian Li^{1,2}, Jun Ding^{1,2}, Feng Liang^{1,2}, Ekaterina Gusev^{1,2}, Orsolya
Lapohos^{1,2}, Gregory J Fonseca^{1,2}, Eva Kaufmann^{1,2}, Maziar Divangahi^{1,2,3}, Basil J Petrof^{1,2}

¹ Meakins-Christie Laboratories, Translational Research in Respiratory Diseases
Program, Research Institute of the McGill University Health Centre, 1001 Decarie
Boulevard, EM3-2219, Montreal, Quebec, Canada H4A 3J1


² Department of Medicine, McGill University Health Centre, 1001 Decarie Boulevard,
D5, Montreal, Quebec, Canada H4A 3J1

³ Department of Microbiology and Immunology, McGill University, Duff Medical Building,
3775 University Street, Montreal, Quebec, Canada H3A 2B4


Necrotic phase



Fibrotic phase



21
 22 **Supplementary Figure 1: Lack of STAT6 phosphorylation in mdx BMDM.** Levels of
 23 p-STAT6 in total cell lysate of WT and mdx BMDM were evaluated by western blot at
 24 necrotic (top panel) and fibrotic (bottom panel) phases of the disease. WT BMDM
 25 treated with 20 ng/ml IL4 for 2 hours, served as a positive control (Ctrl, in the top panel).
 26 Total STAT6 was detected in all samples, and actin served as an additional loading
 27 control. Each lane represents an independent biological sample obtained from a
 28 different animal, and all experimental replicates are shown in the figure.




29

30 **Supplementary Figure 2: mdx BMDM at the fibrotic phase of disease show non-**
 31 **specific amplified responses to heterologous stimuli.** BMDM generated from WT
 32 and mdx mice at the fibrotic phase of disease were exposed to (a) LPS (100 ng/ml) +
 33 IFN γ (20 ng/ml) and IL4 (20 ng/ml) (n=4/group for WT, n=5/group for mdx), (b)
 34 fibrinogen (1 mg/ml) (n=4/group for WT, n=5/group for mdx), or (c) β -glucan (100 μ g/ml)
 35 (n=4/group for WT, n=5/group for mdx except IL6 at 24h n=4). Bar graphs show mRNA
 36 transcript levels of prototypical pro-inflammatory (“M1”) and anti-inflammatory (“M2”)
 37 marker genes at 4 and 24 hours after exposure. All values are expressed relative to the
 38 mean basal WT (unstimulated) level determined on the same PCR plate. Data
 39 represent means \pm SEM of biologically independent samples from different mice.
 40 * P <0.05 vs unstimulated WT BMDM and † P <0.05 vs stimulated WT BMDM at a given

41 time point (one-way ANOVA followed by Tukey post-hoc test, two-tailed). See Source

42 Data file for the exact P values.

43



44

45

Supplementary Figure 3: BMDM from preneurotic mdx mice and cardiotoxin-

46

injured mice do not exhibit amplified responses to heterologous stimuli. BMDM

47


from WT and mdx mice at the preneurotic phase of disease were exposed to (a) LPS +

48

IFN γ or IL4 (n=4/group) (b) fibrinogen (n=4/group), or (c) β -glucan (n=4/group except

49 TGF β in mdx 24h group n=3). Bar graphs show mRNA transcript levels of prototypical
50 pro-inflammatory (“M1”) and anti-inflammatory (“M2”) marker genes at 4 and 24 hours
51 after exposure. **(d-e)** BMDM generated from uninjured and cardiotoxin-injured WT were
52 exposed to heterologous stimuli as in (a-c) (n=4/group for Uninjured, n=5/group for
53 Injured). All values are expressed relative to the mean basal WT level determined on
54 the same PCR plate. Data represent means \pm SEM of biologically independent samples
55 from different mice. * P <0.05 vs unstimulated WT/Uninjured BMDM and † P <0.05 vs
56 stimulated WT/Uninjured BMDM (one-way ANOVA followed by Tukey post-hoc test,
57 two-tailed). See Source Data file for the exact P values.

58




59

60 **Supplementary Figure 4: M1 and M2 marker gene expression after “training” by**
 61 **muscle extract or serum in vitro.** As indicated in Fig. 4a, WT BMDM were exposed for
 62 24 hours to muscle extract (ME) derived from either (a) WT (n=5 per group) or (b) mdx
 63 muscles (n=5/group except for TGF β at 24h n=4). Gene expression was measured

64 immediately after ME exposure (24 hours) as well as after removal of the ME stimulus
65 and subsequent “resting” of the cells (5 days). The dashed line indicates the mean
66 basal expression level for PBS-exposed WT BMDM at each time point. **(c-d)** Expression
67 of inflammatory genes 8 hours after fibrinogen exposure in WT BMDM previously
68 “trained” with mdx-ME at **(c)** different concentrations (0.1, 0.5 and 1 mg/ml) for 24 hours
69 (n=4 per group), or **(d)** different exposure durations (2, 8, 24 hours) using the same
70 concentration (1 mg/ml) (n=4 per group). Data are expressed relative to the PBS-trained
71 group identically stimulated with fibrinogen. **(e)** Identically to the ME protocol (Fig. 4a),
72 WT BMDM (n=4 per group) were “trained” with WT or mdx (4-6 weeks old) serum (5%)
73 followed by resting for 5 days and secondary stimulation with fibrinogen for 8 hours. The
74 graph shows the M1 and M2 markers gene expression levels relative to the PBS-trained
75 group stimulated with fibrinogen. **(f)** Donor macrophage (defined as CD45.2+CD11c-
76 CD11b+F4/80+) number (left panel) and percentage (right panel) in the tibialis anterior
77 (TA) muscle of mice (n=5 per group) transplanted with WT or mdx bone marrow as
78 shown in Fig. 4d. There were no differences between groups. All data represent means
79 \pm SEM of independent biological or mice (**a-b, f**: *P<0.05 unpaired t-test, two-tailed; **c-e**:
80 *P<0.05 vs. PBS- trained WT BMDM one-way ANOVA followed by Tukey post-hoc test,
81 two-tailed). See Source Data file for the exact P values.

82



83


84 **Supplementary Figure 5: Pathway analysis (Reactome database) for the Gene-**

85 **based Patterns (GP) designated GP2, GP3 and GP4 for H3K27me3. Pathway**

86 **enrichment analysis is shown for genes showing the (a) GP2, (b) GP3, and (c) GP4**

87 **configurations. The vertical line indicates the cut-off P value = 0.05. The extended gene**

88 **lists are found in the Supplementary Data 2 table.**



89

90 **Supplementary Figure 6: Transcription factor enrichment analysis for H3K27me3**

91 **in WT, mdx and mdxTLR4^{-/-} BMDM. (a) Stacked heatmaps of the Peak-based Pattern**

92 **(PP) analysis showing the dynamically regulated patterns in mdx versus WT**

93 **(designated PP1 to PP4); the normalized H3K27me3 read intensity is plotted ±12 kb**

94 **over the center of peaks. The values in parentheses indicate the percentages for each**

95 **pattern (I=Increased and U=Unchanged relative to Input) as follows: PP1=IUI,**


96 **PP2=IUU, PP3=UII and PP4=UIU. (b-c) Transcription factor enrichment Reactome**

97 **pathway analysis for (b) PP1, and (c) PP2 patterns. Vertical lines indicate the cut-off P**


98 **value = 0.05. The extended lists for these data can be found in Supplementary Data 4**

99 **and 5 tables.**

a




b



100

101 **Supplementary Figure 7: H3K4me3 promoter occupancy in BMDM.** ChIP-qPCR
 102 was performed to determine promoter region occupancy of H3K4me3 on both M1 and
 103 M2 marker genes in (a) WT versus mdx BMDM (n=5 per group) and (b) mdx versus
 104 mdxTLR4^{-/-} BMDM (n=5 per group). IgG antibody was used as a control for non-specific
 105 binding of antibody. Data represent means \pm SEM of independent biological samples
 106 from different mice. *P<0.05 (unpaired t-test, two tailed). See Source Data file for the
 107 exact P values.




108

109

110

Supplementary Figure 8: Gene-based Pattern (GP) analysis of H3K27ac ChIP sequencing for WT, mdx and mdxTLR4^{-/-} BMDM at the necrotic phase of disease.

111 (a) Violin/box plots representing normalized intensity fold change (H3K27ac vs. Input) in
112 the region 5kb upstream to the transcription start site (TSS) of all genes across the
113 whole genome; *P<0.0001 compared to WT BMDM, and † P<0.0001 compared to the
114 mdx group (two-sided Mann-Whitney U-test). Maxima and minima are shown at the
115 extreme limits of the plot, box boundaries indicate the 25th and 75th percentiles,
116 whiskers represent the 10th and 90th percentiles, and the horizontal line within the box
117 denotes the median value. (b) Heatmaps showing different Gene-based Patterns
118 (I=Increased and U=Unchanged relative to Input) in order of frequency: GP1 (IUU), GP2
119 (UIU), GP3 (IUI) and GP4 (UII) of the normalized H3K27ac read intensity (proportional
120 to red color intensity) in the 5 kb promoter region of the genes. The values in
121 parentheses indicate the percentages for each pattern. (c-f) Pathway enrichment
122 analysis (Reactome database) for genes showing the GP1-4 configuration (see
123 Supplementary Data 1 and 2 tables for the extended list of all Gene-based Patterns and
124 enriched pathways, respectively). The vertical line indicates the cut-off P value = 0.05.
125



126

127 **Supplementary Figure 9: Transcription factor enrichment analysis for H3K27ac in**

128 **WT, mdx and mdxTLR4^{-/-} BMDM. (a)** Heatmaps showing different Peak-based

129 Patterns (I=Increased and U=Unchanged relative to Input) in order of frequency: PP1

130 (IUU), PP2 (UIU), PP3 (IUI) and PP4 (UII) of the normalized H3K27ac read intensity


131 (proportional to red color intensity) in the 24 kb nearby region around the peak. The

132 values in parentheses indicate the percentages for each pattern. Transcription factor

133 enrichment Reactome pathway analysis for **(b)** PP1 and **(c)** PP2 patterns are shown.

134 Vertical lines indicate the cut-off P value = 0.05. The extended lists for these data can

135 be found in Supplementary Data 4 and 5 tables.



136

137 **Supplementary Figure 10: Phenotype of macrophages in WT and mdx limb**


138 **muscles.** Tibialis anterior (TA) muscles from WT and mdx mice were processed and
 139 the percentages of pro-inflammatory macrophages (iNOS+ CD206- population, in upper
 140 panel and iNOS+ TGFβ- population, in lower panel) were determined by flow cytometry.

141 Data are mean values ± SEM of independent biological samples from different mice

142 (n=3/group). *P<0.05 (unpaired t-test, two-tailed). See Source Data file for the exact P

143 values.

144



145

146 **Supplementary Figure 11: Phenotype of host macrophages in injured muscles**

147 **after adoptive transfer with WT or mdx BMDM.** No significant differences in host (a)

148 pro-inflammatory macrophages (iNOS+ CD206- TGFβ- population) (n=10/group) and

149 (b) anti-inflammatory macrophages (iNOS- CD206+ TGFβ+ population) (n=9/group),

150 were found in comparisons between mice adoptively transferred with either WT or mdx

151 BM. Similarly, no significant differences in the host (c) pro-inflammatory macrophages

152 (n=5/group) and (d) anti-inflammatory macrophages (n=5/group) were observed


153 between groups adoptively transferred with either mdx or mdxTLR4^{-/-} BM. All data are

154 means ± SEM of independent biological samples from different mice. There are no

155 significant differences between groups (unpaired t-test, two-tailed). See Source Data file

156 for the exact P values.

157



158

159 **Supplementary Figure 12: Gating strategy.** Flow cytometry gating strategies are

160 shown for: (a) Hematopoietic progenitor cells, (b) Innate myeloid cells, and (c)

161 Lymphocytes, in bone marrow. (d) Gating strategy for the analysis of pro- and anti-

162 inflammatory macrophages in the injured host (CD45.1) limb muscles of mice after

163 adoptive transfer with donor (CD45.2) bone marrow cells.